Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Net income was −$105M. Operating cash flow of −$88M less capital expenditure of $209,000 left free cash flow of −$88M.
Last 5 fiscal years
| Fiscal year | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | – |
| Research & development | 5.0 | 13.8 | 4.7 | 1.0 | 101 |
| Operating income | −9.8 | −19.3 | −10.6 | −7.3 | −122 |
| Interest expense | 0.0 | – | – | – | – |
| Pre-tax income | −9.7 | −19.3 | – | – | −105 |
| Income tax | −0.0 | 0.0 | 0.0 | 0.0 | – |
| Net income | −9.7 | −19.3 | −9.9 | −5.3 | −105 |
| Diluted EPS | −2.07 | −1.39 | −0.69 | −0.37 | – |
| Diluted shares | 4.7 | 13.9 | 14.4 | 14.4 | – |
| Fiscal year | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 49.1 | 53.4 | 42.4 | 37.4 | 46.9 |
| Current assets | 50.0 | 54.4 | 42.7 | 37.6 | 344 |
| Net PP&E | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 |
| Total assets | 50.4 | 54.9 | 43.1 | 37.9 | 489 |
| Payables | 1.8 | 1.1 | 0.3 | 0.4 | 4.2 |
| Current liabilities | 3.5 | 3.5 | 1.1 | 0.6 | 15.4 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 | – |
| Total liabilities | 3.9 | 3.9 | 1.4 | 0.8 | 16.7 |
| Shareholders' equity | 46.5 | 51.0 | 41.7 | 37.0 | 472 |
| Fiscal year | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −7.7 | −18.8 | −10.9 | −5.0 | −88.2 |
| Capital expenditure | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 |
| Free cash flow | −7.7 | −18.8 | −10.9 | −5.0 | −88.4 |
| Depreciation & amortisation | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Stock-based compensation | 0.0 | 0.5 | 0.6 | 0.7 | 24.2 |
| Fiscal year | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2025 |
|---|---|---|---|---|---|
| Return on equityBlank when equity is negative | −20.9% | −37.9% | −23.8% | −14.4% | −22.3% |
| ROCEEBIT ÷ (assets − current liabilities) | −20.8% | −37.6% | −25.3% | −19.6% | −25.8% |
| Cash conversion (CFO ÷ net income) | 0.79x | 0.97x | 1.10x | 0.94x | 0.84x |
| Interest cover | −1085x | – | – | – | – |
| Debt ÷ equity | 0.00x | 0.00x | 0.00x | 0.00x | – |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | −49.1 | −53.4 | −42.4 | −37.4 | – |
| Current ratio | 14.3x | 15.6x | 37.7x | 59.0x | 22.4x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.